



Published in final edited form as:

Adv Healthc Mater. 2020 April ; 9(8): e1901656. doi:10.1002/adhm.201901656.

Mechanobiology Assays with Applications in Cardiomyocyte Biology and Cardiotoxicity

Cheavar A. Blair^{1,2}, Beth L. Pruitt^{1,2,3,*}

¹Department of mechanical Engineering, University of California Santa Barbara, Santa Barbara, CA, USA.

²Biomolecular Science and Engineering, University of California Santa Barbara, Santa Barbara, CA, USA.

³Molecular, Cellular and Developmental Biology, University of California Santa Barbara, Santa Barbara, CA, USA.

Abstract

The mechanical phenotype of cardiomyocytes is essential to their function as the motor unit of the heart. Traditionally, testing of drugs for cardiotoxic effects has relied on primary cardiomyocytes from animal models and focused on short-term, electrophysiological and arrhythmogenic effects. However, primary cardiomyocytes present challenges arising from their limited viability in culture, and tissue from animal models suffers from a mismatch in their physiology to that of human heart muscle. Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) can address these challenges. They also offer the potential to study not only electrophysiological effects but also changes in cardiomyocyte contractile and mechanical function in response to cardiotoxic drugs. With growing recognition of the long-term cardiotoxic effects of some drugs on subcellular structure and function, there is increasing interest in using hiPSC-CMs for in vitro cardiotoxicity studies. In this review, we provide a brief overview of techniques that can be used to quantify changes in the active force cardiomyocytes generate and variations in their inherent stiffness in response to cardiotoxic drugs. We conclude by discussing the application of these tools in understanding how cardiotoxic drugs directly impact the mechanobiology of cardiomyocytes and how cardiomyocytes sense and respond to mechanical load at the cellular level.

Keywords

mechanobiology; cardiotoxicity; Human induced pluripotent stem cell; cardiomyocytes; heart failure; mechanotransduction

Introduction

The ability of the heart to contract and pump blood into the pulmonary and systemic circulations is driven by the contractile force cardiomyocytes (CMs) generate. Under normal

*Corresponding author blp@ucsb.edu.

Financial conflicts of interest: None

conditions, these cells are dynamic and have an intrinsic ability to alter force production in response to changes in hemodynamic pressures and adrenergic stimulation to maintain cardiac output. At the molecular level, this unique ability is driven by the interaction between the sarcomeric proteins actin and myosin. As more myosin heads bind to actin filaments, force production increases. Conversely, a reduction in myosin heads bound to actin filaments will result in less than optimal contractile force. While this is true for healthy hearts, cardiac dysfunction resulting from heart attacks, cardiomyopathies, or cardiotoxicity can lessen the ability of CMs to modulate contractile force in response to environmental changes.^[1–5] With most of these defects, CMs are unable to produce enough contractile force to maintain cardiac output leading to heart failure. In some cases, such as hypertrophic cardiomyopathy, cardiomyocytes become hypercontractile and generate higher than normal contractile forces.^[6, 7]

In addition to contracting and creating force to move blood, CMs must be able to relax and maintain an appropriate resting tension that allows for proper ventricular filling and cardiac function.^[8] In CMs, resting tension is mainly governed by the elastic sarcomeric protein titin, but is also impacted by cytoskeletal proteins including microtubules, and extracellular proteins such as collagen.^[9–13] When CMs are stretched beyond their resting tension, they develop a passive force that impacts cellular stiffness. Reports have shown that titin is responsible for up to 90% of the passive forces CMs experience.^[9, 14–16] Thus, this sarcomeric protein is a primary determinant of CM stiffness. Titin's impact on cellular stiffness is mainly dictated by the expression ratio of the small (N2B) to large (N2BA) isoforms of the protein. CMs that experience high passive stiffness correlate with a higher expression ratio of the smaller stiffer N2B isoform, whereas more compliant CMs have a higher ratio of the larger more compliant N2BA isoform.^[17–19] While the impact of heart attacks and cardiomyopathies that result in heart failure on cardiac stiffness and contractile force has been extensively studied,^[20–23] it remains unclear how cardiotoxic drugs alter these properties.

One of the challenges when conducting drug screening assays for cardiotoxicity is the availability of cellular models that can recapitulate the physiology of adult human CMs in vitro. While primary human CMs can be isolated from explanted hearts for these assays, the propagation of these cells in vitro has been difficult. The use of cell lines from animal models that over-express human cardiac ion channels have also been applied to cardiotoxicity studies,^[24] but these models are often inaccurate at predicting human cardiac drug responses as the physiology of these cells differ from humans. Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) overcome many of the challenges with current models as they closely recapitulate the physiology of adult human CMs, can be readily differentiated and can be maintained for months in culture.^[25–27] Moreover, with growing recognition of the long-term cardiotoxic effects of some drugs on subcellular structure and function, there is increasing interest in using hiPSC-CMs for cardiotoxicity studies. hiPSC-CMs not only address many challenges of physiology mismatch with animal models and primary cell viability, they also offer the potential to study electrophysiological effects and changes in cardiomyocyte contractile function and mechanical in response to cardiotoxic drugs.

In this review, we first define cardiotoxic processes and agents. Then, we provide a brief overview of techniques that can be used to quantify changes in the forces CMs actively generate and passively experience in response to cardiotoxic drugs. We will focus on assays that have utilized live cell models because the advent of hiPSC-CMs promises a source of CMs that can be matched to the genetic background of patients and can display similar physiology to adult human CMs.^[28–30] We conclude by discussing the application of these tools in understanding how cardiotoxic drugs impact the mechanobiology of CMs, or how CMs sense and respond to mechanical load at the cellular level.

Cardiotoxic agents and CM function

The cardiotoxic side-effects of drug therapies were first described in the 1940s when it was noted that treatment with digitalis and local anesthetics adversely impacted cardiac function.^[31] Today it is widely known that treatment with chemotherapies such as anthracyclines (e.g., doxorubicin), and other drugs including anti-arrhythmic (e.g., Quinidine), anti-psychotic (e.g., chlorpromazine), and anti-histamines (e.g., Astemizole) can cause cardiotoxic side-effects.^[32–35] Amongst these agents, the most concerning are chemotherapies, as there is increasing recognition that traditional (e.g., doxorubicin and paclitaxel) and novel (e.g., trastuzumab, sunitinib, Pembrolizumab) cancer drugs are leading to cardiovascular toxicity and heart failure.^[36–40] While the exact mechanism of cancer drug-induced cardiotoxicity is not well understood, it is clear that chemotherapies can adversely impact several aspects of cardiac function, including electrophysiology, mitochondrial function, contractility and viability (Table 1).^[41–46] Changes to these structural and functional components can, in turn, alter the intrinsic ability of CMs to contract and generate active force independent of external load or applied stretch.

Proarrhythmic drugs are also of concern, several of these drugs have led to altered electrophysiological function in CMs that can be deadly. With the formation of the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative, there has been an increase in studies examining the impact of cardiotoxic agents on electrophysiological properties (e.g., calcium handling, ion channel conductance) of CMs. The CiPA initiative was established as a new paradigm to detect and remove proarrhythmic drugs from patient care that can lead to a fatal arrhythmia such as Torsade de Pointes.^[47] In addition to impacting the electrophysiological function of CMs, these proarrhythmic drugs can also alter contractility and mitochondrial function (Table 1).

While the impact of proarrhythmic and cancer drugs on CM function is evident, it is less clear how these cardiotoxic agents impact the structural components and extracellular environment around CMs that can alter passive forces. These studies are needed because cardiovascular disease related to oncology therapies is of increasing concern for emerging cancer therapies.^[48] Such structure-function studies will provide a more complete picture of how cancer drugs and other toxic compounds alter the active and passive forces of CMs and enable therapeutic interventions to detect and mitigate the secondary effects of cardiac dysfunction and heart failure.

Assays used in cardiotoxicity studies to measure active force

The active force CMs generate is driven by the interaction between the sarcomeric proteins actin and myosin. These proteins are able to interact and produce force when Ca^{2+} ions bind the troponin complex which through a series of events opens binding sites on actin filaments that allow myosin heads to attach and pull actin filaments inward to contract the cell and generate force (Figure 1). Several assays have been reported to measure changes in active forces in response to cardiotoxic compounds in vitro at the cellular and tissue levels. The functional readout of contractile “force” is commonly reported (Table 2). Importantly, force is always derived from displacement measurements coupled with mechanical models and underlying assumptions about material properties. For example, traction force microscopy (TFM) tracks the displacement of fiducials (beads) in a substrate using high-speed video to determine changes in the amplitude of a contractile field exerted by a cell. These displacements are then mapped to forces by assumptions about mechanical properties and boundary conditions.^[83–87] From these forces and deformations, one can estimate the work or strain energy in a contractile cycle. Several other assays focus on ensemble cell motions or edge displacements and estimate a more limited set of biophysical parameters like rates and connectivity. Below, we review in order of prevalence, how several such mechanobiology assays and parameters have or could be used to answer questions about the impact of cardiotoxic agents on active force.

A. Video microscopy

High-speed (typically >40 Hz) video capture of the contraction and relaxation cycles is a commonly used technique to assess changes contractile force in response to cardiotoxic agents in CMs. These measurements are frequently performed in drug screening and development assays in conjunction with electrophysiological measurements.^[33, 88] Although the recording of videos for these assays is straightforward, data analysis is more complex. In contrast to isolated primary CMs from animal and human heart tissue, unstructured hiPSC-CMs lack a defined cellular membrane, sarcomere organization, and direction of contraction.^[89, 90] Macro-scale motions can be mapped using particle tracking algorithms^[91–93], and while motion maps can be extracted from such data, many material and boundary assumptions must be made to transform to force estimates. Since, monolayers of hiPSC-CMs or unstructured single hiPSC-CM lack well defined morphological features, these motion analysis methods have difficulty accurately tracking and quantifying changes in displacement in these models. With the adoption of hiPSC-CMs as models for drug development and screening,^[94–96] newer analysis methods seek to account for the lack of organized sarcomere, non-uniformity of contraction, and lack of pronounced membrane edges.^[89, 90, 97–99] Such algorithms track displacement in hiPSC-CMs either by monitoring changes in pixel intensity or applying particle image velocimetry methods to generate vector maps that track displacement in all directions regardless of sarcomere organization or detectable edges.^[91, 99, 100] This is fundamentally different from analysis tools that relied on raster-line scanning of periodic features and edges (as found in primary cells) to detect changes in sarcomere motion or the displacement of the edges of CMs.^[101–103]

Several labs have deployed advanced video microscopy analyses of drug-induced changes in contractile function of hiPSC-CMs, from single cells to 3D tissue constructs.

[81, 88, 98, 104–106] Common mechanical readouts include changes in peak contraction/relaxation amplitudes, contraction/relaxation velocities, and beat rate (Table 2). For example, Sala et al. deployed their “MUSCLEMOTION” analysis software to study the cardiotoxic agent Nifedipine (a Ca^{2+} channel blocker used to treat hypertension) and learn that it reduces contraction amplitudes in single-cell hiPSC-CM, hiPSC-CM monolayers, and 3D tissue constructs.^[98] Similarly, Maddah et al. used their “Pulse” video analysis tool to observe a reduction in the beat rate of hiPSC-CMs monolayers exposed to the cardiotoxic agents Verapamil (Ca^{2+} blocker) and Cisapride (a drug used to treat gastric-emptying disorders).^[97]

Live cell models can also be coupled with Ca^{2+} dyes,^[107] genetically encoded voltage sensors,^[108] and fluorescently labeled organelles (e.g., mitochondria) or structural proteins (e.g., sarcomeres). Video analysis tools can then correlate structural parameters with Ca^{2+} handling, electrophysiological function, structural damage or disorganization, and mechanical parameters (See Table 2). Changes to electrophysiological function, Ca^{2+} handling, or cellular damage can greatly impact the amount of active force CMs can generate. “SarcTrack” is one such video analysis tool that tracks the displacement of fluorescently labeled sarcomeric proteins to reveal changes to sarcomere length and shortening.^[109] Not surprisingly, sarcomere length changes have been correlated with contractile force.^[110] Toepfer et al. used of SarcTrack to detect changes to sarcomere function in response to drug treatment using a small molecule that alters myosin function.^[109] Monitoring such changes at the level of sarcomere structure and function will enable new insights into mechanisms of action of cardiotoxic compounds. With continued improvements in imaging tools and analysis software, video microscopy analysis will continue to be a cornerstone of drug discovery and screening assays. When combined with quantitative assays of hiPSC-CM contractile work output, such assays offer the potential for semi-automated pipelines to assess change to contractile function under drug treatments.

In the following sections, we focus on biomechanical assays that when combined with molecular biology manipulations and video microscopy, enable insight into the *mechanobiology* of cardiotoxic responses. By mechanobiology, we mean the changes in biophysical phenotype and the role of mechanical load in cell signaling and in exacerbating cell responses to cardiotoxic compounds.

B. Traction force microscopy

TFM is a technique that is used to quantitatively determine the amount of force CMs exert against a substrate by monitoring the displacements of fiducials embedded in the substrate (Figure 2). Video microscopy alone provides data on changes in contractile displacements and rates (Table 2) by measuring the displacement of CMs over time. By capturing an additional video channel of fluorescent bead motions in a deformable substrate under a cell, TFM can be used to quantify active force, power, and strain energy that CMs exert on a substrate. We refer interested readers to several excellent reviews on the instrumentation and device preparation required, image-processing algorithms and subsequent post-processing analysis principles for TFM.^[111–114]

TFM can be used to determine the active forces generated by single cells and 2D sheets of CMs, and with appropriate model construction and confocal imaging, within 3D tissue constructs.^[115–119] Because of the post-processing computation required, TFM has not been widely adopted for drug discovery and screening. However, unlike high-throughput video microscopy assays performed on plastic or glass, TFM offers advantages for research into mechanobiology mechanisms because the substrate stiffness can be matched to physiological stiffness in disease and development. Substrate stiffness is a key factor in functional measurements on CMs, as the stiffness of the substrate can significantly impact the amount of active forces hiPSC-CMs generate.^[110, 120, 121] Thus, performing TFM using substrate stiffnesses similar to the physiological environment can be advantageous for examining the impact of drugs on CM mechanical function. TFM is also readily combined with protein patterning techniques to constrain hiPSC-CM size and shape,^[110] such cell patterning enhances the subcellular structure, maturity, and biophysical function.

TFM has been deployed in drug screening assays to demonstrate the impact of several compounds on CM function.^[90, 98] For example, Kijlstra et al. used TFM and reported a reduction in single-cell hiPSC-CM active force production in response to verapamil, and dofetilide (anti-arrhythmic drug), two known cardiotoxic agents.^[90] We have also used TFM to show the application of the technique in assessing the effects of contractile agonists and stimulants on force generation in single-cell hiPSC-CMs.^[122] With the advantages TFM offers over traditional video microscopy assays in terms of quantitative measurements and substrate stiffness manipulation TFM holds the potential to examine underlying mechanisms and the impact of cardiotoxic agents on the active forces CMs produce.

C. Microposts for single-cell and engineered heart tissue force measurements

Micropost platforms use vertical, deformable beams to estimate the force of attached CMs (Figure 2). This mechanobiological assay converts micropost motion (imaged at the top of the post) to force using a simpler mechanical model for beam bending and assumptions about the material properties of the microposts. Pairs of posts have been used with 3D cardiac tissue constructs encircling the posts; while arrays of microposts have been used to study monolayers and single CMs attached to the top of the posts (Figure 2). Micropost arrays have been used by several labs to measure the contractile forces generated by single-cell CMs.^[123–129] This technique is very similar to single-cell TFM assays in that the traction forces generated by CMs create displacement in the substrate. These displacements are used to calculate the amount of active force from the known spring constant of the beams.^[123] Micropost fabrication does require specialized tools or access to a lithographically defined mold. Once manufactured, however, microposts are relatively shelf-stable compared to TFM hydrogel substrates that change stiffness appreciably in about a week.^[130] Another advantage is that post displacement is directly related to the force CMs apply to that individual post, making force calculations straightforward and less computationally intensive.^[111] However, microposts also present challenges. Matching the stiffness of microposts to physiological conditions is not straightforward because they have an effective out of plane stiffness that is an order of magnitude stiffer than in-plane stiffness. They also present a discontinuous bio-interface where cells can sag or engulf the microposts depending on the protein functionalization strategy.

Measuring changes to CM stiffness in response to cardiotoxic agents

CMs have an inherent stiffness that is mainly governed by the expression ratios of the N2BA (more compliant) and N2B (stiffer) isoforms of the elastic sarcomeric protein titin (Figure 1).^[146] In healthy adult hearts, the expression ratios of N2BA: N2B in CMs are 30:70 to 40:60 which provides the relatively high tensile stiffness needed for proper cardiac function.^[147] Studies have shown that the expression ratio of these two isoforms shifts during developmental and diseased states, with the titin-based passive tension getting higher/stiffer throughout development (switch to more N2B) and more compliant (switch to more N2BA) with disease.^[20, 148–150] In addition to isoform switching, mutations in the titin protein that leads to truncation or altered phosphorylation can also alter CM stiffness and lead to cardiac dysfunction.^[151–154] Changes to the stiffness individual CMs to a lesser degree can also be impacted by microtubules, as these cytoskeletal proteins have been shown to alter the passive stiffness of CMs especially in response to post-translational modifications during disease states.^[13, 155]

Several techniques have been used to measure the stiffness of live individual CMs in vitro including AFM, carbon fibers, and microfluidics-based and traditional micropipette aspiration assays.^[143, 156–160] Of these methods, AFM is the most commonly used to assess stiffness changes in CMs. Similar to the active force measurements mentioned earlier, stiffness measurements using AFM are performed with a cantilever. To measure CM stiffness using AFM, the cantilever is used to create a precise indentation in the CM membrane that creates a force that is tracked along a force vs. indentation curve. The data from this curve are then fitted to estimate a bulk elastic modulus for the cell (this procedure typically uses a Hertz model, though we note that cells are neither elastic nor homogeneous). Through a similar indentation method, the carbon fiber technique has also been used to determine the stiffness of CMs. However, instead of using a cantilever as in AFM, a small microsphere attached to the carbon fiber is used to create the indentation.^[161] Micropipette aspiration is the oldest and simplest of these techniques. The technique is conducted by placing the tip of a pulled glass pipette on an individual cell and, by controlling applied suction, deforming the cell as it is pulled into the micropipette. The elastic properties of the cell are then inferred by Laplace's law and the changes in cell geometry. Micropipette aspiration was first used by Brady et al. in the 1970s to measure the mechanical properties of living individually isolated rat CMs using a single barrel pipette.^[160] The technique has since evolved from using a single barrel pipettes to double-barrel pipettes (offers better cell attachment and wider scope of mechanical measurements) and in some applications, to semi-automated microfluidics with controllers to increase the precision and throughput.^[157, 162–164]

Of these, only AFM has been reported for assessing the impact of cardiotoxic agents on CM stiffness. For example, Yue et al. used the technique to show that the cancer drug doxorubicin reduced stiffness of isolated mouse primary CMs.^[145] It was not reported in the study whether the reduction in stiffness was due changes to titin, microtubules or other cellular structures. However, patient data from breast cancer patients shows that cancer drugs can cause frameshift mutation in titin, reducing cardiac compliance and ultimately leading to cardiomyopathy.^[165] More studies are needed to understand the cardiotoxic effects of

chemotherapeutic and other cardiotoxic agents on CM stiffness to understand the mechanisms by which these compounds induce these changes.

Mechanotransduction and Cardiotoxicity

CMs must be able to sense mechanical loads in order to respond to their environment (changes in hemodynamics, ECM content, etc.). The mechanobiology processes by which these cells sense and transmit mechanical signals to initiate a biomechanical response are referred to as mechanosensing and mechanotransduction respectively.^[166] There have been several proteins and complexes identified as mechanical sensors, signal transducers, and structural transmission conduits of mechanical loads in CMs, including integrins, the dystrophin-dystroglycan complex, the sarcomere, talin and other elements of the cytoskeleton.^[167–169] In CMs, mechanotransduction of mechanical loads are essential to cellular function, development, and maladaptive responses, as the transmission of these signals throughout the cell can significantly alter cellular structure and function.^[167] For example, Jian et al. have shown that mechanical load can significantly impact the action potential duration, calcium transients, and contractility of single CMs.^[170]

The impact of cardiotoxic agents on the ability of CMs to sense and transmit stress and strain is not fully understood. However, reports from studies in rabbits and humans have demonstrated altered expression of integrins and titin genes, respectively, in response to cancer drug treatment.^[165, 171] In both cases, rabbits and humans developed heart failure. While it is unclear if the changes in the gene expression of integrins and titin resulted in altered protein function leading to any causal effects, it is widely known that changes in the function of integrins and/or titin can impact contractility and the transmission of mechanical signals.^[167, 172] More research in this area is needed to determine the effects of cardiotoxic agents on CMs ability to sense and transmit mechanical signals.

To address these questions, mechanobiological techniques will play an invaluable role as these assays can provide insights into the mechanisms CMs use to sense and transmit mechanical loads. For example, Pandey et al. used nanopillars (nanoscale post arrays) to show that CMs can sense matrix rigidity through a combination of muscle and non-muscle myosin activity.^[173] Using the same technique, they also demonstrated that the stretching of the protein talin which can impact mechanotransduction of mechanical signals depends on matrix stiffness, myofibrillar and non-myofibrillar tension.^[173] While these investigators did not apply any cardiotoxic agents to the CMs in their studies, their work provides experimental data that mechanobiological techniques like post arrays can be used to answer questions on how CMs sense and respond to their environment and cardiotoxic agents.

Future Outlook

The use of hiPSC-CMs for cardiotoxicity studies will continue to grow as these cells more closely recapitulate the physiology and function of human adult CMs than in vitro cell models from animals. Although electrophysiological assays to identify arrhythmogenic effects of cardiotoxic agents remains a primary standard for pre-clinical cardiotoxicity screening, assessing concomitant changes in the mechanical phenotype of CMs during the screening process is also needed to unravel mechanisms of disease progression.^[174] As

discussed in this review, one of the main challenges for adopting the current mechanobiological techniques in a pre-clinical drug screening process is their low throughput. Though techniques such as TFM and AFM can be used to probe CMs for mechanistic discovery, as well as provide a quantitative assessment of changes to CM function, they still require significant technical expertise. However, with the continued development and automation of these techniques, as well as other methods such as the EHT/micropost systems, mechanobiological assays to assess changes in CM function will eventually make their way in the drug screening and development process. Future work is also needed to bridge single cell, tissue, and organism level data to rationalize the outputs across these different scales.

Acknowledgments

Funding:

American Heart Association 17CSA33590101

NIH 1 UG3 TR002588

NIH NIGMS RM1GM131981

Reference

1. Mulieri LA, et al., Altered myocardial force-frequency relation in human heart failure. *Circulation*, 1992 85(5): p. 1743–50. [PubMed: 1572031]
2. Vikhorev PG and Vikhoreva NN, Cardiomyopathies and Related Changes in Contractility of Human Heart Muscle. *International journal of molecular sciences*, 2018 19(8): p. 2234.
3. Ujfalusi Z, et al., Dilated cardiomyopathy myosin mutants have reduced force-generating capacity. *J Biol Chem*, 2018 293(23): p. 9017–9029. [PubMed: 29666183]
4. Witjas-Paalberends ER, et al., Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy. *Cardiovascular Research*, 2013 99(3): p. 432–441. [PubMed: 23674513]
5. Cuomo A, et al., Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients. *Cardiac failure review*, 2019 5(2): p. 112–118. [PubMed: 31179022]
6. Spudich JA, Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations. *Pflugers Arch*, 2019 471(5): p. 701–717. [PubMed: 30767072]
7. Adhikari AS, et al., β -Cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity. *Nature Communications*, 2019 10(1): p. 2685.
8. Shiels HA, White E, and J, The Frank-Starling mechanism in vertebrate cardiac myocytes. *Biol*, 2008 211: p. 2005–13.
9. Granzier HL and Irving TC, Passive tension in cardiac muscle: contribution of collagen, titin, microtubules, and intermediate filaments. *Biophys J*, 1995 68(3): p. 1027–44. [PubMed: 7756523]
10. Bollen IAE, et al., Cardiomyocyte Hypocontractility and Reduced Myofibril Density in End-Stage Pediatric Cardiomyopathy. *Frontiers in Physiology*, 2017 8(1103).
11. Chaturvedi Rajiv R, et al., Passive Stiffness of Myocardium From Congenital Heart Disease and Implications for Diastole. *Circulation*, 2010 121(8): p. 979–988. [PubMed: 20159832]
12. Anderson BR and Granzier HL, Titin-based tension in the cardiac sarcomere: molecular origin and physiological adaptations. *Progress in biophysics and molecular biology*, 2012 110(2–3): p. 204–217. [PubMed: 22910434]
13. Robison P, et al., Detyrosinated microtubules buckle and bear load in contracting cardiomyocytes. *Science*, 2016 352(6284): p. aaf0659.

14. Brady AJ, Mechanical properties of isolated cardiac myocytes. *Physiol Rev*, 1991 71(2): p. 413–28. [PubMed: 2006219]
15. Granzier HL and Labeit S, The giant protein titin: a major player in myocardial mechanics, signaling, and disease. *Circ Res*, 2004 94(3): p. 284–95. [PubMed: 14976139]
16. Freiburg A, et al., Series of exon-skipping events in the elastic spring region of titin as the structural basis for myofibrillar elastic diversity. *Circ Res*, 2000 86(11): p. 1114–21. [PubMed: 10850961]
17. Cazorla O, et al., Differential Expression of Cardiac Titin Isoforms and Modulation of Cellular Stiffness. *Circulation Research*, 2000 86(1): p. 59–67. [PubMed: 10625306]
18. Prado LG, et al., Isoform diversity of giant proteins in relation to passive and active contractile properties of rabbit skeletal muscles. *J Gen Physiol*, 2005 126(5): p. 461–80. [PubMed: 16230467]
19. Fukuda N, et al., Titin isoform variance and length dependence of activation in skinned bovine cardiac muscle. *The Journal of physiology*, 2003 553(Pt 1): p. 147–154. [PubMed: 12963792]
20. Neagoe C, et al., Titin Isoform Switch in Ischemic Human Heart Disease. *Circulation*, 2002 106(11): p. 1333–1341. [PubMed: 12221049]
21. Makarenko I, et al., Passive stiffness changes caused by upregulation of compliant titin isoforms in human dilated cardiomyopathy hearts. *Circ Res*, 2004 95(7): p. 708–16. [PubMed: 15345656]
22. Nagueh SF, et al., Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy. *Circulation*, 2004 110(2): p. 155–62. [PubMed: 15238456]
23. Borbely A, et al., Cardiomyocyte stiffness in diastolic heart failure. *Circulation*, 2005 111(6): p. 774–81. [PubMed: 15699264]
24. Fermi B, et al., A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm. *J Biomol Screen*, 2016 21(1): p. 1–11. [PubMed: 26170255]
25. Burridge PW, et al., Chemically defined generation of human cardiomyocytes. *Nat Methods*, 2014 11(8): p. 855–60. [PubMed: 24930130]
26. Lian X, et al., Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions. *Nat Protoc*, 2013 8(1): p. 162–75. [PubMed: 23257984]
27. Mummery CL, et al., Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. *Circ Res*, 2012 111(3): p. 344–58. [PubMed: 22821908]
28. Mummery CL, Perspectives on the Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Biomedical Research. *Stem Cell Reports*, 2018 11(6): p. 1306–1311. [PubMed: 30540958]
29. Protze SI, Lee JH, and Keller GM, Human Pluripotent Stem Cell-Derived Cardiovascular Cells: From Developmental Biology to Therapeutic Applications. *Cell Stem Cell*, 2019 25(3): p. 311–327. [PubMed: 31491395]
30. Yang X, Pabon L, and Murry CE, Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes. *Circ Res*, 2014 114(3): p. 511–23. [PubMed: 24481842]
31. Chung R, Ghosh AK, and Banerjee A, Cardiotoxicity: precision medicine with imprecise definitions. *Open Heart*, 2018 5(2): p. e000774.
32. Colatsky T, et al., The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative — Update on progress. *Journal of Pharmacological and Toxicological Methods*, 2016 81: p. 15–20. [PubMed: 27282641]
33. Magdy T, et al., Human Induced Pluripotent Stem Cell (hiPSC)-Derived Cells to Assess Drug Cardiotoxicity: Opportunities and Problems. *Annu Rev Pharmacol Toxicol*, 2018 58: p. 83–103. [PubMed: 28992430]
34. Guo L, et al., Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. *Toxicol Sci*, 2013 136(2): p. 581–94. [PubMed: 24052561]
35. Li X, et al., Cardiotoxicity screening: a review of rapid-throughput in vitro approaches. *Arch Toxicol*, 2016 90(8): p. 1803–16. [PubMed: 26676948]

36. Chatterjee K, et al., Doxorubicin Cardiomyopathy. *Cardiology*, 2010 115(2): p. 155–162. [PubMed: 20016174]
37. Kumar S, et al., Doxorubicin-induced cardiomyopathy 17 years after chemotherapy. *Texas Heart Institute journal*, 2012 39(3): p. 424–427. [PubMed: 22719160]
38. Florescu M, Cinteza M, and Vinereanu D, Chemotherapy-induced Cardiotoxicity. *Maedica*, 2013 8(1): p. 59–67. [PubMed: 24023601]
39. Sharma A, et al., High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. *Sci Transl Med*, 2017 9(377).
40. Varricchi G, et al., Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. *Curr Med Chem*, 2018 25(11): p. 1327–1339. [PubMed: 28403786]
41. Crumb WJ Jr., et al., An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel. *J Pharmacol Toxicol Methods*, 2016 81: p. 251–62. [PubMed: 27060526]
42. Mercurio V, et al., Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs. *Journal of Cardiac Failure*, 2016 22(6): p. 449–458. [PubMed: 27103426]
43. Babiker HM, et al., Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. *Crit Rev Oncol Hematol*, 2018 126: p. 186–200. [PubMed: 29759560]
44. Wang G, et al., Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. *Nat Med*, 2014 20(6): p. 616–23. [PubMed: 24813252]
45. Toyama Y, et al., Effects of taxol and Colcemid on myofibrillogenesis. *Proc Natl Acad Sci U S A*, 1982 79(21): p. 6556–60. [PubMed: 6128733]
46. Howarth FC, et al., Effect of the microtubule polymerizing agent taxol on contraction, Ca²⁺ transient and L-type Ca²⁺ current in rat ventricular myocytes. *J Physiol*, 1999 516 (Pt 2): p. 409–19. [PubMed: 10087341]
47. Gong Y-N, Guy C, Olauson H, Becker JU, Yang M, Fitzgerald P, et al. ESCRT-III acts downstream of MLKL to regulate necroptotic cell death and its consequences. *Cell*. 2017;169:286–300.e16. doi:10.1016/j.cell.2017.03.020.
48. Gilchrist Susan C, et al., Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association. *Circulation*, 2019 139(21): p. e997–e1012. [PubMed: 30955352]
49. Milnes JT, et al., Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide. *J Pharmacol Toxicol Methods*, 2010 61(2): p. 178–91. [PubMed: 20172036]
50. Zhang XP, et al., Dofetilide enhances the contractility of rat ventricular myocytes via augmentation of Na⁺-Ca²⁺ exchange. *Cardiovasc Drugs Ther*, 2009 23(3): p. 207–14. [PubMed: 19221884]
51. Harris K, et al., Comparison of Electrophysiological Data From Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes to Functional Preclinical Safety Assays. *Toxicological Sciences*, 2013 134(2): p. 412–426. [PubMed: 23690542]
52. Nademanee K, et al., Frequency-dependent effects of quinidine on the ventricular action potential and QRS duration in humans. *Circulation*, 1990 81(3): p. 790–6. [PubMed: 2306831]
53. Zhang X, et al., Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment. *Journal of Pharmacological and Toxicological Methods*, 2016 81: p. 201–216. [PubMed: 27282640]
54. Hess Marilyn E. and Haugaard N, Studies of the Effect of Antiarrhythmic Drugs on Carbohydrate Metabolism of Rat Heart Muscle in Vitro. *Circulation Research*, 1958 6(3): p. 256–259. [PubMed: 13523803]
55. Zhao Q, et al., Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes. *Stem cell research & therapy*, 2017 8(1): p. 54–54. [PubMed: 28279214]
56. El-Battrawy I, et al., Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. *Journal of the American Heart Association*. 7(7): p. e007394.

57. Anderson JL and Prystowsky EN, Sotalol: An important new antiarrhythmic. *American Heart Journal*, 1999 137(3): p. 388–409. [PubMed: 10047618]
58. Campbell TJ, Gavaghan TP, and Morgan JJ, Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial. *British Heart Journal*, 1985 54(1): p. 86–90. [PubMed: 3893488]
59. Puri PS and Bing RJ, Effects on Myocardial Contractility, Hemodynamics and Cardiac Metabolism of a New Beta-Adrenergic Blocking Drug, Sotalol. *CHEST*, 1969 55(3): p. 235–239.
60. Drolet B, et al., Block of the Rapid Component of the Delayed Rectifier Potassium Current by the Prokinetic Agent Cisapride Underlies Drug-Related Lengthening of the QT Interval. *Circulation*, 1998 97(2): p. 204–210. [PubMed: 9445174]
61. Tack J, et al., Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. *Alimentary pharmacology & therapeutics*, 2012 35(7): p. 745–767. [PubMed: 22356640]
62. Nguyen N, et al., Adult Human Primary Cardiomyocyte-Based Model for the Simultaneous Prediction of Drug-Induced Inotropic and Pro-arrhythmia Risk. *Frontiers in physiology*, 2017 8: p. 1073–1073. [PubMed: 29311989]
63. Yu Z, et al., Allosteric Modulation of Kv11.1 (hERG) Channels Protects Against Drug-Induced Ventricular Arrhythmias. *Circulation: Arrhythmia and Electrophysiology*, 2016 9(4): p. e003439.
64. Woosley RL, et al., Mechanism of the cardiotoxic actions of terfenadine. *Jama*, 1993 269(12): p. 1532–6. [PubMed: 8445816]
65. Lu Y. and Wang Z, Terfenadine block of sodium current in canine atrial myocytes. *J Cardiovasc Pharmacol*, 1999 33(3): p. 507–13. [PubMed: 10069689]
66. Watanabe H, et al., Usefulness of cardiotoxicity assessment using calcium transient in human induced pluripotent stem cell-derived cardiomyocytes. *J Toxicol Sci*, 2017 42(4): p. 519–527. [PubMed: 28717111]
67. He J, Ma J, and Anson B, Use of pluripotent stem cell-derived cardiomyocytes to understand mechanisms of cardiotoxic compounds. 2009.
68. Zhang S, et al., Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. *Circ Res*, 1999 84(9): p. 989–98. [PubMed: 10325236]
69. Pointon A, et al., Assessment of Cardiomyocyte Contraction in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. *Toxicological Sciences*, 2014 144(2): p. 227–237. [PubMed: 25538221]
70. Sharp W, Simpson DG, Terracio L, & Borg TK, Signal Transduction and Myofibrillogenesis in Isolated Neonatal Heart Myocytes In Vitro In Biomechanics of Active Movement and Division of Cells (2013). 1994: Springer Berlin Heidelberg.
71. Mohan IK, et al., Cardioprotection by HO-4038, a novel verapamil derivative, targeted against ischemia and reperfusion-mediated acute myocardial infarction. *American journal of physiology. Heart and circulatory physiology*, 2009 296(1): p. H140–H151. [PubMed: 18978191]
72. Buza V, Rajagopalan B, and Curtis Anne B, Cancer Treatment-Induced Arrhythmias. *Circulation: Arrhythmia and Electrophysiology*, 2017 10(8): p. e005443.
73. Barac A, Quo Vadis Trastuzumab? Navigating Cardiac Safety Risk Estimates With Complex Cancer Treatments, 2019 7(3): p. 225–227.
74. Dogan I, et al., Inhibition of ErbB2 by herceptin reduces viability and survival, induces apoptosis and oxidative stress in Calu-3 cell line. *Mol Cell Biochem*, 2011 347(1–2): p. 41–51. [PubMed: 20936496]
75. Bello CL, et al., Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. *Clin Cancer Res*, 2009 15(22): p. 7045–52. [PubMed: 19903787]
76. Jacob F, et al., Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue. *PLoS One*, 2016 11(2): p. e0145937.
77. Kim DM, et al., Identification of a Mitochondrial DNA Polymerase Affecting Cardiotoxicity of Sunitinib Using a Genome-Wide Screening on *S. pombe* Deletion Library. *Toxicol Sci*, 2016 149(1): p. 4–14. [PubMed: 26385865]

78. Schneider C, et al., The Anti-Cancer Multikinase Inhibitor Sorafenib Impairs Cardiac Contractility by Reducing Phospholamban Phosphorylation and Sarcoplasmic Calcium Transients. *Sci Rep*, 2018 8(1): p. 5295. [PubMed: 29593308]
79. Will Y, et al., Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells. *Toxicological Sciences*, 2008 106(1): p. 153–161. [PubMed: 18664550]
80. Zhang K, et al., Paclitaxel accelerates spontaneous calcium oscillations in cardiomyocytes by interacting with NCS-1 and the InsP3R. *Journal of molecular and cellular cardiology*, 2010 49(5): p. 829–835. [PubMed: 20801127]
81. Burrige PW, et al., Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. *Nat Med*, 2016 22(5): p. 547–56. [PubMed: 27089514]
82. Maillet A, et al., Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes. *Scientific reports*, 2016 6: p. 25333–25333. [PubMed: 27142468]
83. Schwarz US and Soine JR, Traction force microscopy on soft elastic substrates: A guide to recent computational advances. *Biochim Biophys Acta*, 2015 1853(11 Pt B): p. 3095–104. [PubMed: 26026889]
84. Plotnikov SV, et al., High-resolution traction force microscopy. *Methods Cell Biol*, 2014 123: p. 367–94. [PubMed: 24974038]
85. Style RW, et al., Traction force microscopy in physics and biology. *Soft Matter*, 2014 10(23): p. 4047–4055. [PubMed: 24740485]
86. Polacheck WJ and Chen CS, Measuring cell-generated forces: a guide to the available tools. *Nat Methods*, 2016 13(5): p. 415–23. [PubMed: 27123817]
87. Kraning-Rush CM, et al., Quantifying traction stresses in adherent cells. *Methods Cell Biol*, 2012 110 SRC - Google Scholar: p. 139–78. [PubMed: 22482948]
88. Sharma A, et al., Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity. *Nat Protoc*, 2018 13(12): p. 3018–3041. [PubMed: 30413796]
89. Ahola A, et al., Video image-based analysis of single human induced pluripotent stem cell derived cardiomyocyte beating dynamics using digital image correlation. *Biomed Eng Online*, 2014 13: p. 39. [PubMed: 24708714]
90. Kijlstra JD, et al., Integrated Analysis of Contractile Kinetics, Force Generation, and Electrical Activity in Single Human Stem Cell-Derived Cardiomyocytes. *Stem Cell Reports*, 2015 5(6): p. 1226–1238. [PubMed: 26626178]
91. Estruch-Samper D, Particle Image Velocimetry RJ Adrian and Westerweel J, Cambridge University Press, The Edinburgh Building, Shaftesbury Road, Cambridge, CB2 2RU, UK. 2011. 558pp. £75. ISBN 978-0-521-44008-0. *The Aeronautical Journal* (1968), 2012 116(1176): p. 219–220.
92. Rajasingh S, et al., Contactless Particle Image Velocimetry (PIV) Method of Screening Drugs Using Human iPSC-derived Cardiomyocytes. *Journal of Molecular and Cellular Cardiology*, 2017 112: p. 145.
93. Taylor ZJ, et al., Long-Duration Time-Resolved PIV to Study Unsteady Aerodynamics. *IEEE Transactions on Instrumentation and Measurement*, 2010 59(12): p. 3262–3269.
94. Smith AS, et al., Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening. *Biotechnol Adv*, 2017 35(1): p. 77–94. [PubMed: 28007615]
95. Zhang J, et al., Combining hiPSCs and Human Genetics: Major Applications in Drug Development. *Cell Stem Cell*, 2017 21(2): p. 161–165. [PubMed: 28777942]
96. Suh W, A new era of disease modeling and drug discovery using induced pluripotent stem cells. *Arch Pharm Res*, 2017 40(1): p. 1–12. [PubMed: 27921262]
97. Maddah M, et al., A non-invasive platform for functional characterization of stem-cell-derived cardiomyocytes with applications in cardiotoxicity testing. *Stem cell reports*, 2015 4(4): p. 621–631. [PubMed: 25801505]
98. Sala L, et al., MUSCLEMOTION: A Versatile Open Software Tool to Quantify Cardiomyocyte and Cardiac Muscle Contraction In Vitro and In Vivo. *Circ Res*, 2018 122(3): p. e5–e16. [PubMed: 29282212]

99. Huebsch N, et al., Automated Video-Based Analysis of Contractility and Calcium Flux in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Cultured over Different Spatial Scales. *Tissue Eng Part C Methods*, 2015 21(5): p. 467–79. [PubMed: 25333967]
100. Maddah M. and Loewke K, Automated, non-invasive characterization of stem cell-derived cardiomyocytes from phase-contrast microscopy. *Med Image Comput Comput Assist Interv*, 2014 17(Pt 1): p. 57–64.
101. Steadman BW, et al., A video system for measuring motion in contracting heart cells. *IEEE Trans Biomed Eng*, 1988 35(4): p. 264–72. [PubMed: 3360456]
102. Delbridge LM and Roos KP, Optical methods to evaluate the contractile function of unloaded isolated cardiac myocytes. *J Mol Cell Cardiol*, 1997 29(1): p. 11–25. [PubMed: 9040017]
103. Bazan C, et al., Image Processing Techniques for Assessing Contractility in Isolated Adult Cardiac Myocytes. *International Journal of Biomedical Imaging*, 2009 2009: p. 11.
104. Pointon A, et al., From the Cover: High-Throughput Imaging of Cardiac Microtissues for the Assessment of Cardiac Contraction during Drug Discovery. *Toxicol Sci*, 2017 155(2): p. 444–457. [PubMed: 28069985]
105. Takeda M, et al., Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells. *Tissue Engineering Part C: Methods*, 2017 24(1): p. 56–67. [PubMed: 28967302]
106. Feaster TK, et al., Matrigel Mattress: A Method for the Generation of Single Contracting Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. *Circ Res*, 2015 117(12): p. 995–1000. [PubMed: 26429802]
107. Lock JT, Parker I, and Smith IF, A comparison of fluorescent Ca²⁺ indicators for imaging local Ca²⁺ signals in cultured cells. *Cell Calcium*, 2015 58(6): p. 638–648. [PubMed: 26572560]
108. Suzuki J, Kanemaru K, and Iino M, Genetically Encoded Fluorescent Indicators for Organellar Calcium Imaging. *Biophys J*, 2016 111(6): p. 1119–1131. [PubMed: 27477268]
109. Toepfer Christopher N, et al., SarcTrack. *Circulation Research*, 2019 124(8): p. 1172–1183. [PubMed: 30700234]
110. Ribeiro AJ, et al., Contractility of single cardiomyocytes differentiated from pluripotent stem cells depends on physiological shape and substrate stiffness. *Proc Natl Acad Sci U S A*, 2015 112(41): p. 12705–10. [PubMed: 26417073]
111. Roca-Cusachs P, Conte V, and Trepas X, Quantifying forces in cell biology. *Nature Cell Biology*, 2017 19: p. 742. [PubMed: 28628082]
112. Mulligan JA, et al., Traction Force Microscopy for Noninvasive Imaging of Cell Forces, in *Biomechanics in Oncology*, Dong C, Zahir N, and Konstantopoulos K, Editors. 2018, Springer International Publishing: Cham p. 319–349.
113. Fleissner F. and Parekh SH, Imaging mechanotransduction: Seeing forces from molecules to cells. *Current Opinion in Biomedical Engineering*, 2018 5: p. 58–65.
114. Colin-York H. and Fritzsche M, The future of traction force microscopy. *Current Opinion in Biomedical Engineering*, 2018 5: p. 1–5.
115. Steinwachs J, et al., Three-dimensional force microscopy of cells in biopolymer networks. *Nature Methods*, 2015 13: p. 171. [PubMed: 26641311]
116. Polio SR, et al., Topographical control of multiple cell adhesion molecules for traction force microscopy. *Integr Biol (Camb)*, 2014 6(3): p. 357–65. [PubMed: 24441735]
117. Maskarinec SA, et al., Quantifying cellular traction forces in three dimensions. *Proc Natl Acad Sci U S A*, 2009 106(52): p. 22108–13. [PubMed: 20018765]
118. Zundel M, Ehret AE, and Mazza E, Factors influencing the determination of cell traction forces. *PLoS One*, 2017 12(2): p. e0172927.
119. Han SJ, et al., Traction microscopy to identify force modulation in subresolution adhesions. *Nat Methods*, 2015 12(7): p. 653–6. [PubMed: 26030446]
120. Hazeltine LB, et al., Effects of substrate mechanics on contractility of cardiomyocytes generated from human pluripotent stem cells. *Int J Cell Biol*, 2012 2012: p. 508294.
121. Wheelwright M, et al., Investigation of human iPSC-derived cardiac myocyte functional maturation by single cell traction force microscopy. *PLoS One*, 2018 13(4): p. e0194909.

122. Ribeiro AJS, et al., Multi-Imaging Method to Assay the Contractile Mechanical Output of Micropatterned Human iPSC-Derived Cardiac Myocytes. *Circ Res*, 2017 120(10): p. 1572–1583. [PubMed: 28400398]
123. Beussman KM, et al., Micropost arrays for measuring stem cell-derived cardiomyocyte contractility. *Methods*, 2016 94: p. 43–50. [PubMed: 26344757]
124. Zhao Y. and Zhang X, Cellular mechanics study in cardiac myocytes using PDMS pillars array. *Sensors and Actuators A: Physical*, 2006 125(2): p. 398–404.
125. Tanaka Y, et al., Demonstration of a PDMS-based bio-microactuator using cultured cardiomyocytes to drive polymer micropillars. *Lab Chip*, 2006 6(2): p. 230–5. [PubMed: 16450032]
126. Ribeiro AJS, et al., Stable, Covalent Attachment of Laminin to Microposts Improves the Contractility of Mouse Neonatal Cardiomyocytes. *ACS Applied Materials & Interfaces*, 2014 6(17): p. 15516–15526. [PubMed: 25133578]
127. Taylor RE, et al., Sacrificial layer technique for axial force post assay of immature cardiomyocytes. *Biomedical Microdevices*, 2013 15(1): p. 171–181. [PubMed: 23007494]
128. Kim K, et al., Calibrated micropost arrays for biomechanical characterisation of cardiomyocytes. *Micro Nano*, 2011 6 SRC - GoogleScholar: p. 317–322.
129. Rodriguez ML, et al., Measuring the contractile forces of human induced pluripotent stem cell-derived cardiomyocytes with arrays of microposts. *J Biomech Eng*, 2014 136(5): p. 051005.
130. Denisin AK and Pruitt BL, Tuning the Range of Polyacrylamide Gel Stiffness for Mechanobiology Applications. *ACS Appl Mater Interfaces*, 2016 8(34): p. 21893–902. [PubMed: 26816386]
131. Feric NT, et al., Engineered Cardiac Tissues Generated in the Biowire II: A Platform for Human-Based Drug Discovery. *Toxicological Sciences*, 2019 172(1): p. 89–97.
132. Brown GE and Khetani SR, Microfabrication of liver and heart tissues for drug development. *Philos Trans R Soc Lond B Biol Sci*, 2018 373(1750).
133. Zimmermann WH, et al., Tissue Engineering of a Differentiated Cardiac Muscle Construct. *Circulation Research*, 2002 90(2): p. 223–230. [PubMed: 11834716]
134. Mannhardt I, et al., Human Engineered Heart Tissue: Analysis of Contractile Force. *Stem Cell Reports*, 2016 7(1): p. 29–42. [PubMed: 27211213]
135. Schaaf S, et al., Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. *PLoS One*, 2011 6(10): p. e26397.
136. Takeda M, et al., Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells. *Tissue Eng Part C Methods*, 2018 24(1): p. 56–67. [PubMed: 28967302]
137. Mannhardt I, et al., Piezo-bending actuators for isometric or auxotonic contraction analysis of engineered heart tissue. *J Tissue Eng Regen Med*, 2019 13(1): p. 3–11. [PubMed: 30334614]
138. Conant G, et al., High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model. *Stem Cell Rev Rep*, 2017 13(3): p. 335–346. [PubMed: 28429185]
139. Hansen A, et al., Development of a Drug Screening Platform Based on Engineered Heart Tissue. *Circulation Research*, 2010 107(1): p. 35–44. [PubMed: 20448218]
140. Hutter JL and Bechhoefer J, Calibration of atomic-force microscope tips. *Review of Scientific Instruments*, 1993 64(7): p. 1868–1873.
141. Domke J, et al., Mapping the mechanical pulse of single cardiomyocytes with the atomic force microscope. *European Biophysics Journal*, 1999 28(3): p. 179–186. [PubMed: 10192933]
142. Shroff SG, Saner DR, and Lal R, Dynamic micromechanical properties of cultured rat atrial myocytes measured by atomic force microscopy. *Am J Physiol*, 1995 269(1 Pt 1): p. C286–92. [PubMed: 7631757]
143. Liu J, et al., Atomic force mechanobiology of pluripotent stem cell-derived cardiomyocytes. *PLoS One*, 2012 7(5): p. e37559.
144. Chang W-T, et al., Characterization of the Mechanodynamic Response of Cardiomyocytes with Atomic Force Microscopy. *Analytical Chemistry*, 2013 85(3): p. 1395–1400. [PubMed: 23265281]

145. Yue T, et al., Quantifying Drug-Induced Nanomechanics and Mechanical Effects to Single Cardiomyocytes for Optimal Drug Administration To Minimize Cardiotoxicity. *Langmuir*, 2016 32(7): p. 1909–19. [PubMed: 26738425]
146. Linke WA, Titin Gene and Protein Functions in Passive and Active Muscle. *Annu Rev Physiol*, 2018 80: p. 389–411. [PubMed: 29131758]
147. Neagoe C, et al., Gigantic variety: expression patterns of titin isoforms in striated muscles and consequences for myofibrillar passive stiffness. *Journal of Muscle Research & Cell Motility*, 2003 24(2): p. 175–189. [PubMed: 14609029]
148. Opitz CA, et al., Developmentally regulated switching of titin size alters myofibrillar stiffness in the perinatal heart. *Circ Res*, 2004 94(7): p. 967–75. [PubMed: 14988228]
149. Lahmers S, et al., Developmental control of titin isoform expression and passive stiffness in fetal and neonatal myocardium. *Circ Res*, 2004 94(4): p. 505–13. [PubMed: 14707027]
150. LeWinter MM and Granzier HL, Cardiac titin and heart disease. *Journal of cardiovascular pharmacology*, 2014 63(3): p. 207–212. [PubMed: 24072177]
151. Herman DS, et al., Truncations of titin causing dilated cardiomyopathy. *N Engl J Med*, 2012 366(7): p. 619–28. [PubMed: 22335739]
152. Schafer S, et al., Titin-truncating variants affect heart function in disease cohorts and the general population. *Nat Genet*, 2017 49(1): p. 46–53. [PubMed: 27869827]
153. Borbely A, et al., Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. *Circ Res*, 2009 104(6): p. 780–6. [PubMed: 19179657]
154. Hidalgo C, et al., PKC phosphorylation of titin's PEVK element: a novel and conserved pathway for modulating myocardial stiffness. *Circ Res*, 2009 105(7): p. 631–8, 17 p following 638. [PubMed: 19679839]
155. Chen CY, et al., Suppression of detyrosinated microtubules improves cardiomyocyte function in human heart failure. *Nature Medicine*, 2018 24(8): p. 1225–1233.
156. Sugiura S, et al., Carbon fiber technique for the investigation of single-cell mechanics in intact cardiac myocytes. *Nat Protoc*, 2006 1(3): p. 1453–7. [PubMed: 17406434]
157. Davidson PM, et al., High-throughput microfluidic micropipette aspiration device to probe time-scale dependent nuclear mechanics in intact cells. *Lab Chip*, 2019.
158. Hochmuth RM, Micropipette aspiration of living cells. *J Biomech*, 2000 33(1): p. 15–22. [PubMed: 10609514]
159. Zhang C, et al., Dynamic Model for Characterizing Contractile Behaviors and Mechanical Properties of a Cardiomyocyte. *Biophys J*, 2018 114(1): p. 188–200. [PubMed: 29320686]
160. Brady AJ, Tan ST, and Ricchiuti NV, Contractile force measured in unskinned isolated adult rat heart fibres. *Nature*, 1979 282(5740): p. 728–729. [PubMed: 514354]
161. Nishimura S, et al., Microtubules modulate the stiffness of cardiomyocytes against shear stress. *Circ Res*, 2006 98(1): p. 81–7. [PubMed: 16306445]
162. Copelas L, et al., A method for recording isometric tension development by isolated cardiac myocytes: transducer attachment with fibrin glue. *Pflügers Archiv*, 1987 408(3): p. 315–317. [PubMed: 2437526]
163. Bazan C, et al., Contractility assessment in enzymatically isolated cardiomyocytes. *Biophysical reviews*, 2012 4(3): p. 231–243. [PubMed: 28510074]
164. Siedlik MJ, Varner VD, and Nelson CM, Pushing, pulling, and squeezing our way to understanding mechanotransduction. *Methods*, 2016 94: p. 4–12. [PubMed: 26318086]
165. Linschoten M, et al., Truncating Titin (TTN) Variants in Chemotherapy-Induced Cardiomyopathy. *J Card Fail*, 2017 23(6): p. 476–479. [PubMed: 28315399]
166. Iskratsch T, Wolfenson H, and Sheetz MP, Appreciating force and shape — the rise of mechanotransduction in cell biology. *Nature Reviews Molecular Cell Biology*, 2014 15: p. 825. [PubMed: 25355507]
167. Lyon Robert C, et al., Mechanotransduction in Cardiac Hypertrophy and Failure. *Circulation Research*, 2015 116(8): p. 1462–1476. [PubMed: 25858069]

168. Saucerman JJ, et al., Mechanical regulation of gene expression in cardiac myocytes and fibroblasts. *Nature Reviews Cardiology*, 2019 16(6): p. 361–378. [PubMed: 30683889]
169. Sheehy SP, Grosberg A, and Parker KK, The contribution of cellular mechanotransduction to cardiomyocyte form and function. *Biomech Model Mechanobiol*, 2012 11(8): p. 1227–39. [PubMed: 22772714]
170. Jian Z, et al., Mechanical Load Effects on Cardiomyocyte Action Potential, Calcium Transient, and Contraction Revealed by using a Novel Patch-Clamp-in-Gel Technology. *Biophysical Journal*, 2018 114(3, Supplement 1): p. 620a.
171. Ichikawa Y, et al., Modulation of caveolins, integrins and plasma membrane repair proteins in anthracycline-induced heart failure in rabbits. *PLoS One*, 2017 12(5): p. e0177660.
172. Israeli-Rosenberg S, et al., Integrins and integrin-associated proteins in the cardiac myocyte. *Circ Res*, 2014 114(3): p. 572–586. [PubMed: 24481847]
173. Pandey P, et al., Cardiomyocytes Sense Matrix Rigidity through a Combination of Muscle and Non-muscle Myosin Contractions. *Dev Cell*, 2018 44(3): p. 326–336.e3.
174. Yang X. and Papoian T, Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity. *J Appl Toxicol*, 2018.




Figure 1. Cellular structures that impact passive stiffness and force generation in CMs. Representative CM with cellular organelles, ions, and protein structures (**top left**). The two isoforms of titin found in CMs (**top right**). Proteins within the sarcomere that are involved in force generation (**bottom right**).




Figure 2. Mechanobiological techniques for active force measurements in CMs. (A-C) Video microscopy of relaxed (A) and contracted (B) CMs. Representative trace used to determine functional changes (C). (D-G) Traction force microscopy (TFM) of relaxed (D) and contracted (E) CM on hydrogel substrate with fiducials. Representative brightfield and traction force map (F) of CM. (G) Representative traces of the summed traction forces CMs generate in response to drug treatment. Micropost platforms (H-K). (H, I) micropost array with contracted (H) and relaxed (I) CM. (J) Relaxed and (K) contracted engineered heart

tissue (EHT) on micropost. (**L, M**) Atomic force microscopy (AFM) cantilever on a relaxed (**L**) and contracted (**M**) CM. (**N**) Representative traces used in the determination of functional changes for EHT, AFM, and micropost array measurements.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1.

Example CiPA and cancer drugs that have been identified as cardiotoxic

CiPA drugs	Mechanism of action in cardiomyocytes	Effects on electrophysiology	Effects on contractility	Effects on viability/ O ² consumption
Dofetilide	Block hERG encoded I _{Kr} (delayed rectifier potassium) channels	Prolong QT interval and Increase APD [41, 49]	Enhance contractility in rat ventricular cells [50]	No reports
Quinidine	Blocks fast I _{Na} , slow Ca ²⁺ , and hERG encoded I _{Kr} channels [51]	Increase APD in patients [52]	Reduce beating amplitudes in hiPSC-CMs monolayer [53]	Reduces oxygen consumption in rat heart slices [54], Cardiotoxic to hiPSC-CMs [55]
Sotalol	Non-selective beta-adrenergic blocker [56] Blocks hERG encoded I _{Kr} channels [57]	Increase APD in patients [58]	Lower contractility in dog hearts [59]	No reports
Cisapride	Blocks hERG encoded I _{Kr} channels [60]	Increase QT interval and ADP in patients [61]	Do not alter contractility in human primary cells [62]	Cardiotoxic, reduces cell viability [63]
Terfenadine	Blocks hERG encoded I _{Kr} [64], and I _{Na} [65] channels	Prolongs QT interval in hiPSC-CM monolayer [66]	No effect on contractility in hiPSC-CM monolayer [66]	Reduce cell viability in hiPSC-CM monolayer [67]
Verapamil	Ca ²⁺ channel blocker	Low doses prolong APD. High doses shorten action potential duration [68]	Reduce contractility and sarcomere dynamics in hiPSC-CM monolayer. [69]. Depress myofibril formation [70]	Increase myocardial oxygen [71]
Cancer drugs	Mechanism of action in cardiomyocytes	Effects on electrophysiology	Effects on contractility/ myofibrillar structure	Effects on viability/ O² consumption
Trastuzumab	Monoclonal antibody that targets HER2 receptor	May induce arrhythmias in patients [72]	Decrease left ventricular ejection fraction in patients [73]	Reduce cell viability [74]
Sunitinib	Tyrosine kinase inhibitor	Prolongs QT interval [75]	Declines contractile force in engineered heart tissues made with rat heart cells [76]	Reduces mitochondrial function, and is cardiotoxic [77]
Sorafenib	Tyrosine kinase inhibitor	Reduce Ca ²⁺ content, and re-uptake in the sarcoplasmic reticulum in patient cardiac tissue [78]	Decrease force development in patient cardiac samples [78]	Cardiotoxic [78] Reduce oxygen consumption in rat hearts [79]
Imatinib	Tyrosine kinase inhibitor	No effect on APD in hiPSC-CM monolayer [39]	Declines contractile force in engineered heart tissues made with rat heart cells [76]	Does not alter cell viability in hiPSC-CMs [39]
Paclitaxel	Stabilizes tubulin polymerization	Increase spontaneous Ca ²⁺ oscillations in mice [80]	Reduced mechanical output, depressed myofibril formation [45, 46]	No effect on cell viability in rodents [80]
Doxorubicin	Prevents DNA re-ligation and double-stranded break repair	Impair Ca ²⁺ handling, [81] increase intracellular Ca ²⁺ in hiPSC-CM monolayer [82]	Reduce contractility, degrades myofibrils [36, 44]	Impair metabolic function, reduces O ² consumption in hiPSC-CM monolayer [81]

ADP = Action potential duration

hERG = human ether-a-go-related gene potassium channel

Table 2.

Assays to assess changes in active force in response to cardiotoxic agents in live-cell models

Technique	Mechanical Readouts	Electrophysiological readouts	Structural readouts	Applicable Platforms
Video Microscopy	Beating frequency Time to peak contraction Time from peak to 50% and 90% relaxation	Ca ²⁺ transient amplitude Ca ²⁺ transient duration Ca ²⁺ transient rise and decay times Same readouts can be reported using voltage-sensitive dyes for other ions	Sarcomere length Sarcomere registry Myofibril alignment	Single-cell 2D monolayer 2D organized sheet 3D tissue constructs
Traction force microscopy (TFM)	Beating frequency Beat displacement Relative force Times of contraction/relaxation Velocity of contraction/relaxation Power Force-frequency	*Ca ²⁺ transient amplitude *Ca ²⁺ transient duration *Ca ²⁺ transient rise and decay times *Same readouts can be reported using voltage-sensitive dyes for other ions	*Sarcomere length *Sarcomere registry *Myofibril alignment	Single-cell 2D monolayer 2D organized tissue 3D tissue constructs
Micropost	Beating frequency Beat displacement Relative force Times of contraction/relaxation Velocity of contraction/relaxation Power Force-frequency	*Ca ²⁺ transient amplitude *Ca ²⁺ transient duration *Ca ²⁺ transient rise and decay times *Same readouts can be reported using voltage-sensitive dyes for other ions	*Sarcomere length *Sarcomere registry *Myofibril alignment	Single cells Monolayers 3D tissue constructs
Atomic force microscopy	Beating frequency Vertical force	*Ca ²⁺ transient amplitude *Ca ²⁺ transient duration *Ca ²⁺ transient rise and decay times *Same readouts can be reported using voltage-sensitive dyes for other ions	*Sarcomere length *Sarcomere registry *Myofibril alignment	Single-cell

* In combination with video microscopy and cells with voltage-sensitive dyes or fluorescent labels